Evoke Pharma (NASDAQ:EVOK) Major Shareholder Sells $95,850.00 in Stock

Evoke Pharma, Inc. (NASDAQ:EVOK) major shareholder Roger Klein sold 9,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.65, for a total value of $95,850.00. Following the completion of the transaction, the insider directly owned 29,000 shares in the company, valued at approximately $308,850. This trade represents a 23.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Evoke Pharma Stock Up 0.6%

Shares of EVOK stock traded up $0.06 on Friday, hitting $10.69. The stock had a trading volume of 53,929 shares, compared to its average volume of 760,464. Evoke Pharma, Inc. has a one year low of $1.94 and a one year high of $10.79. The business has a 50 day moving average price of $5.29 and a 200 day moving average price of $4.35. The company has a market cap of $16.68 million, a PE ratio of -4.18 and a beta of -0.14.

Evoke Pharma (NASDAQ:EVOK) last issued its earnings results on Thursday, August 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.32). The business had revenue of $3.75 million for the quarter, compared to the consensus estimate of $3.80 million. Evoke Pharma had a negative return on equity of 99.48% and a negative net margin of 42.07%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on EVOK shares. Wall Street Zen raised Evoke Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, September 7th. Laidlaw downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Evoke Pharma in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evoke Pharma stock. National Wealth Management Group LLC purchased a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned about 5.14% of Evoke Pharma as of its most recent filing with the Securities & Exchange Commission.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.